Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Trial Profile

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Anaesthesia; Postoperative pain
  • Focus Pharmacokinetics
  • Sponsors Pacira Pharmaceuticals
  • Most Recent Events

    • 20 May 2016 Dose of the EXPAREL is changed from 266 mg (20 mL) to 133 mg (10 mL).
    • 08 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 19 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top